Kyverna Therapeutics’ Post

🌟 Exciting News in Medical Innovation! 🌟 Embark on a groundbreaking journey with the revolutionary approach to drug development for lung diseases. 🫁💡 🚀 Accelerating Drug Development for Lung Diseases: A Quantum Leap in Healthcare cutting-edge Organotypic Model System tailored specifically for lung research🌐🔬 In the pursuit of healthier tomorrows, dedicated team of experts has crafted a transformative platform that promises to expedite the drug development process for lung-related ailments. Read the full story here: https://bit.ly/41eWfuH Credit: Luisa Hoffmann, Helmholtz-Gemeinschaft / Helmholtz Association #HLCA #ArtificialIntelligence #lungfibrosis #LungDiseaseMedication #lungcancer #meded #eMednews

Did you know that #Tissue #Factor (TF), also known as #CD142, plays a crucial role in the blood coagulation process? 🌟 This protein is essential for initiating the clotting cascade, which helps our bodies stop bleeding and heal wounds. 🩸 But TF's role doesn't stop there! Recent research has unveiled its involvement in various biological processes, including: 🔬 Tumor growth and metastasis 🧠 Inflammatory responses 💊 Cardiovascular diseases By understanding TF's multifaceted roles, we can develop better treatments for a range of health conditions. Join us in exploring the fascinating world of TF/CD142 and its impact on health and disease! https://lnkd.in/ez4iZPyW #TissueFactor #CD142 #Hemostasis #BloodCoagulation #MedicalResearch #HealthScience #Biotechnology

𝗟𝗮𝗯-𝗚𝗿𝗼𝘄𝗻 𝗟𝘂𝗻𝗴 𝗧𝗶𝘀𝘀𝘂𝗲 𝗖𝗼𝘂𝗹𝗱 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗟𝘂𝗻𝗴 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 🌱 Lab-grown lung tissues unveil fresh insights into the mechanisms of lung disease. 🚧 Challenges persist in lung disease drug development, with many trials failing due to limitations in current lab models. 🔄 Human precision-cut lung slices (hPCLS) stand as a revolutionary model for live lab experiments, offering a closer representation of lung tissue. ⏩ Insights from ongoing hPCLS experiments promise to accelerate the understanding and development of novel therapies for lung diseases. #LungHealthRevolution #InnovationsInDrugDiscovery ➡️ Read this article for more details: https://lnkd.in/eRZ2CJwH

Great news for the community! #Prilenia announces #pridopidine Phase 3 #ALS study plans, supported by clinical data showing slowing of disease progression, increased survival time and reduced worsening of symptoms. Pridopidine is an oral, highly selective, and potent S1R agonist. The S1R protein, highly expressed in the brain and spinal cord, regulates several key processes commonly impaired in various neurodegenerative diseases. Activation of the S1R by pridopidine stimulates multiple cellular protective pathways, including autophagy, axonal transport, mitochondrial energy production and calcium homeostasis. These are essential to neuronal function and survival and may lead to neuroprotective effects—well done! https://lnkd.in/gFCEtmPD

#FDMT - 4DMT Presents Positive Interim Data from Phase 12 AEROW Clinical Trial of Aerosolized 4D710 for ModulatorIneligibleIntolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference https://buff.ly/4c7pX9p Clinically meaningful improvements in ppFEV 1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV 1 50-80%) and >6 months follow up Aerosolized 4D-710 was well tolerated at doses up to 1E15 vg (n=6) ...

When standard of care is exhausted, scientists leaned towards combination of functional precision medicine (FPM) with drug sensitivity testing (DST) to identify treatment options. Results look promising with DST turn around time at 9 days as opposed to 27days through genomic profiling, significant time saved to enable swift treatment option selection by the tending physicians. Have a read, the outcomes are truly encouraging. https://lnkd.in/gbasHdt8

I'm excited to share that our press release for T-Neuro Pharma has been published today, following the announcement of our publication on Alzheimer's disease in @PNAS. Our team has identified a critical event that may occur before the formation of plaques and tangles, potentially enhancing our understanding of the disease’s early mechanisms. Specifically, we have discovered that self-targeting (APP) T cells cause all of the hallmark pathologies including cognitive decline in our animal model. These cells are also found in the brains of Alzheimer's patients, and their levels in the blood can identify a patient early in the disease. We are currently working on leveraging this discovery to develop a blood-based diagnostic tool called the T-Track Diagnostic Biomarker to detect the disease earlier. Future plans include targeting these T-Cells as a therapeutic, offering hope for a brighter future for those affected by the disease. Read the full press release here: https://prn.to/4cENwqL

Going back into production to offer autologous angiogenic cell precursors to no option cardiovascular disease patients, including chronic limb threatening Ischemia. HEM:TSXV is a buy. https://lnkd.in/gBAQaqpX

Did you know that our humanized B-hEPCAM mice (https://lnkd.in/gZ2HNNKJ) and B-NDG mice(https://lnkd.in/epzJmBds) were used in this publication? Our off-the-shelf and custom animal models continuously advance cutting-edge biomedical research. Find your next model here: https://lnkd.in/dtqGuqe #mousemodel #preclinicalresesarch #therapeutics #immunotherapy #celllinedevelopment #geneediting #immunooncology #antibodytherapeutics #drugdiscovery #pharmacology

Transformative advancements in targeted lipid nanoparticles (tLNPs) with DSPE-PEG2000-maleimide! DSPE-PEG2000-maleimide helps researchers achieve the ultimate goal of toxicity-free delivery of nucleic acids, and the broader objective of precision medicine, by enabling the formation of LNPs that will specifically conjugate to antibodies and targeting ligands, delivering lipid-based genes to their intended cellular target. In this latest blog, we zoom in on DSPE-PEG2000-maleimide to explore its utility in improving the specificity and therapeutic potency of tLNPs, and how its effect on nucleic acid delivery unlocks new avenues for developing much-needed therapies for a range of human diseases, from cancer to neurological disorders. Today it’s more about personalized therapies, and DSPE-PEG2000-maleimide stands out as a cutting-edge tool with huge potential for the future of medicine. Keep reading our latest blog for more! https://ow.ly/pCAO50Suzhb #LipidNanoparticles #tLNPs #DSPEPEG2000maleimide #NucleicAcidDelivery #TargetedTherapies #MedicalInnovation #mRNA #HealthcareRevolution #PersonalizedMedicine